BioSpace News Archive

Basilea Pharmaceutica Ltd. announced that it has entered into an asset purchase agreement and a sub-license agreement with SillaJen, Inc. for Basilea’s novel kinase inhibitor, BAL0891, a potential first-in-class mitotic checkpoint inhibitor, that drives aberrant tumor cell division leading to tumor cell death.

NUVISAN ICB GmbH announced that the company has received a grant with the Bill & Melinda Gates Foundation for an integrated program on discovery and early development of novel non-hormonal contraceptive medicines.

XPhyto Therapeutics Corp. is pleased to report that it has filed a patent application for a significant library of novel psychedelic compounds.

Alzheon, Inc. reported statistically significant and clinically relevant plasma biomarker reduction, robust preservation of brain volume, and positive memory effects in Alzheimer’s patients following 12 months of treatment with investigational agent ALZ-801 in its Phase 2 biomarker trial.

ViewRay, Inc. announced that the University of Texas MD Anderson Cancer Center in Houston, Texas purchased a MRIdian® MR-Guided Radiation Therapy System.

Merck, known as MSD outside of the United States and Canada, announced that the company will initiate a new Phase 3 clinical program with once-daily islatravir for the treatment of people with HIV-1 infection.

MediWound Ltd. today announced that the European Medicines Agency (EMA) has validated for review the Type II Variation submitted by MediWound in order to expand the current approved indication for NexoBrid (removal of eschar in adults with deep partial-and full-thickness thermal burns.

Renalytix plc (NASDAQ: RNLX) (LSE: RENX) announces that Ann Berman, non-executive director and chair of the audit and nomination committees, has resigned as a director of the Company for personal reasons effective immediately.

Chroma Medicine, Inc., (Chroma) a genomic medicine company pioneering single-dose epigenetic editing therapeutics, today announced the formation of a Scientific Advisory Board (SAB).

Alkermes plc (Nasdaq: ALKS) today announced the presentation of research related to its psychiatry portfolio at Psych Congress, which began on Sept. 17 and concludes today, Sept. 20 in New Orleans .